Stemline Therapeutic (STML) Stock Price, Forecast & Analysis
USA - NASDAQ:STML -
STML Key Statistics, Chart & Performance
The current stock price of STML is 11.83 null. In the past month the price decreased by -2.75%. In the past year, price decreased by -16.51%.
STML Latest News, Press Relases and Analysis
About STML
Company Profile
Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.
Company Info
Stemline Therapeutic
750 LEXINGTON AVENUE ELEVENTH FLOOR
NEW YORK NY 10022
CEO: Ivan Bergstein
Phone: 646-502-2311
Stemline Therapeutic / STML FAQ
What does Stemline Therapeutic do?
Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.
What is the stock price of Stemline Therapeutic today?
The current stock price of STML is 11.83 null. The price decreased by -1.42% in the last trading session.
What is the dividend status of Stemline Therapeutic?
STML does not pay a dividend.
How is the ChartMill rating for Stemline Therapeutic?
STML has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
STML Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to STML. When comparing the yearly performance of all stocks, STML is one of the better performing stocks in the market, outperforming 93.31% of all stocks.
STML Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to STML. While STML has a great health rating, there are worries on its profitability.
STML Financial Highlights
Over the last trailing twelve months STML reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS increased by 47.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -150.3% | ||
| ROA | -41.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |